BioNTech announces CureVac acquisition for $1.25 billion in stock to strengthen cancer therapy pipeline and mRNA technology ...

BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy to offer cancer treatments using the modality. According to the deal, ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Fortress Biotech, Inc. has announced the acquisition of its subsidiary Checkpoint Therapeutics, Inc. by Sun Pharmaceutical Industries Limited, which closed on May 30, 2025, after receiving ...

MUMBAI, India and PRINCETON, N.J., May 30, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries ... announced the successful completion of its acquisition of Checkpoint Therapeutics, Inc ...

Royalty Pharma plc (NASDAQ:RPRX), a leading funder of innovation across the biopharmaceutical industry with a market capitalization of $19.25 billion and an impressive 99% gross profit margin ...

In this week’s episode of "The Top Line," the former Pfizer chief commercial officer speaks with Fierce Pharma Deputy Editor ... novel technology at a young biotech startup.

STOUGHTON, Mass. (AP) — STOUGHTON, Mass. (AP) — Collegium Pharmaceutical Inc. (COLL) on Thursday reported first-quarter net income of $2.4 million. On a per-share basis, the Stoughton ...